Cowpea mosaic virus (CPMV) is a nucleoprotein nanoparticle that functions as a highly
potent immunomodulator when administered intratumorally and is used as an in situ …

Cowpea mosaic virus (CPMV) is currently in the development pipeline for multiple
biomedical applications, including cancer immunotherapy. In particular the application of …

Cancer immunotherapies are designed to facilitate recognition and elimination of
transformed cells by the immune system. We have established the immunotherapeutic …

Cowpea mosaic virus (CPMV) has been developed as a promising nanoplatform technology
for cancer immunotherapy; when applied as in situ vaccine, CPMV exhibits potent, systemic …

Nanotechnology has tremendous potential to contribute to cancer immunotherapy. The 'in
situ vaccination'immunotherapy strategy directly manipulates identified tumours to overcome …

Cowpea mosaic virus (CPMV) is a plant virus that has been developed for multiple
biomedical and nanotechnology applications, including immunotherapy. Two key platforms …

Viral nanoparticles are self-assembling units that are being developed and applied for a
variety of applications. While most clinical uses involve animal viruses, a plant-derived virus …

We have previously shown the plant virus Cowpea mosaic virus (CPMV) to be an efficacious
in situ cancer vaccine, providing elimination of tumors and tumor-specific immune memory …

Viral immunotherapies are being recognized in cancer treatment, with several currently
approved or undergoing clinical testing. While contemporary approaches have focused on …

In situ vaccination for cancer immunotherapy uses intratumoral administration of small
molecules, proteins, nanoparticles, or viruses that activate pathogen recognition receptors …